British American Tobacco Reports Steady Revenue Forecast and Mid-Single Figure EPS Growth

• BAT expects to maintain its FY revenue in constant currency, with organic growth of 3-5%.
• Growth is expected to be weighted towards the second half of the year.
• The reported growth is impacted by the transfer of the Russian and Belarusian businesses, expected to close in 2023.
• BAT expects mid-single figure constant currency adjusted diluted EPS growth, with a 2% transactional FX headwind.
• The global tobacco industry is expected to see a volume decrease of 3%.
• BAT is making progress towards de-leveraging its balance sheet, with the ambition to return excess cash to shareholders.
• Analysts are bullish on the stock, with 16 buys, 4 holds, and 0 sells.

A look at British American Tobacco Smart Scores

British American Tobacco P.L.C. is a leading tobacco company in the world. It manufactures, markets, and sells cigarettes and other tobacco products including cigars and roll-your-own tobacco. According to Smartkarma Smart Scores, the long-term outlook for British American Tobacco is very positive. The company scores highly on Value and Dividend, with a score of 5 for both factors, indicating that it is well-positioned to generate value and dividends for investors. The company also scores well on Growth, with a score of 3, suggesting that it is on track for steady growth in the future. However, its scores on Resilience and Momentum are lower, with scores of 2, indicating that it may not be as resilient against market fluctuations and not have the same momentum as other companies.

Overall, British American Tobacco has a strong long-term outlook, with high scores on Value and Dividend and a good score on Growth. It may not be as resilient and have the same momentum as other companies, but it is still well-positioned to generate value and dividends for investors in the long-term.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma